{"id":"NCT03568331","sponsor":"Vanda Pharmaceuticals","briefTitle":"Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Efficacy Study of The Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-09","primaryCompletion":"2019-12-27","completion":"2019-12-27","firstPosted":"2018-06-26","resultsPosted":"2024-05-13","lastUpdate":"2024-05-13"},"enrollment":375,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Tradipitant","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tradipitant","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.","primaryOutcome":{"measure":"Reduction of Worst Itch in Atopic Dermatitis","timeFrame":"8 weeks","effectByArm":[{"arm":"Tradipitant","deltaMin":-3.6,"sd":2.8},{"arm":"Placebo","deltaMin":-3.5,"sd":2.75}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":70,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://advandastudy.com/"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":188},"commonTop":["Headache","Upper respiratory tract infection","Diarrhoea","Dermatitis atopic"]}}